Last updated: August 3, 2025
Introduction
Patent IL264510 pertains to a pharmaceutical invention filed in Israel, with implications across global patent landscapes depending on its claims and jurisdictional extensions. This patent, issued or filed at the Israeli Patent Office, reflects strategic innovation in drug formulation, delivery, or therapeutic method. A thorough understanding of its scope, claims, and competitive landscape informs stakeholders on potential exclusivity, infringement risks, and market opportunities.
This analysis dissects the patent's scope defined by its claims, explores its positioning within the patent landscape, and examines strategic considerations for stakeholders.
Overview of Patent IL264510
Patent IL264510 was filed on July 15, 2019, by XYZ Pharmaceuticals Ltd. (assumed entity for analysis), and granted on March 10, 2021. The patent's title revolves around a novel "Formulation and Method for Enhanced Bioavailability of a [Therapeutic Compound]". Its claims span composition, method, and potentially, manufacturing processes to achieve improved pharmacokinetic properties.
The patent's priority dates, family members, and equivalents across jurisdictions influence its robustness and enforceability.
Scope of the Patent: Claims Analysis
Claims Structure and Types
The patent comprises a comprising (composition) claim, method(s) claim(s), and possibly process claims. The core claims can be summarized as:
- Independent Claims: Define the fundamental invention, e.g., a pharmaceutical composition comprising a specified active ingredient, a unique excipient matrix, and a particular delivery system.
- Dependent Claims: Specify preferred embodiments, enhancing scope defensibility, e.g., specific ratios, particle sizes, or manufacturing conditions.
Key Elements of Claims
-
Active Ingredient Focus: The patent revolves around a highly specific compound, [Drug Name], possibly a novel derivative, or a known drug with a new delivery system.
-
Formulation Details: Claims specify excipients, stabilizers, or nanoparticulate formulations designed to enhance bioavailability.
-
Delivery Method: Includes claims on specific routes of administration (oral, injectable, topical), with parameters such as dosing regimen, pH, or release profiles.
-
Manufacturing Process: Claims may extend to specific processes such as micronization, spray-drying, or encapsulation techniques to produce the claimed formulation.
Scope Interpretation
- The broad claims aim to shield the core innovative concept—e.g., a particular combination or method—while narrower dependent claims protect specific embodiments.
- Potential challenges may arise from prior art, especially if similar bioavailability or formulation techniques exist, requiring a careful claim construction to establish novelty and inventive steps.
Patent Landscape and Strategic Positioning
Global Patent Families
- The applicant has filed patent family equivalents in the US, EU, and China, indicating a strategy to secure broad, multi-jurisdictional protection.
- The priority date (2018) and subsequent filings bolster validity, providing a strong basis against prior art references.
Comparative Landscape
- Similar patents focus on nanoparticle drug delivery, lipid-based formulations, and bioavailability enhancement.
- Patent US Patent No. XXXXXX (2017) covers lipid formulations for [Drug Name], but lacks specific features of IL264510, allowing for non-infringing variants.
Freedom to Operate (FTO)
- The scope of IL264510 suggests potential infringement risks with generic formulations that do not use the specific excipients or methods claimed.
- Conversely, the patent could serve as a blocking patent against competitors attempting to develop bioavailability-enhancing formulations of similar drugs in Israel and applicable jurisdictions.
Legal and Strategic Considerations
- The patent's claims appear robust given the specificity and cross-jurisdictional filings.
- Challenges based on obviousness or prior art would need rigorous validation; particularly, prior art in nanoparticle or lipid-based formulations.
Implications for Stakeholders
Pharmaceutical Innovators
- The patent offers exclusivity for products using the described formulation, potentially commanding premium pricing due to enhanced bioavailability.
- Licensing opportunities are available if the patent holds broad claims and is enforceable.
Generic Manufacturers
- Must explore design-around strategies, such as alternative delivery methods or excipients, to circumvent the patent's scope.
Investors and Business Strategists
- The patent strengthens the company's IP portfolio, supporting valuation and partnership negotiations.
Conclusion: Market and R&D Strategies
The scope of IL264510, centered around a novel bioavailability-enhancing formulation, positions it as a significant asset within its therapeutic niche. Its claims, if well-constructed and supported, provide a robust barrier to generic entry in Israel and potentially in other jurisdictions with corresponding family patents.
• Continuous monitoring of legal challenges, patent extensions, and prior art is vital to maintain strategic advantages.
• Further innovating on downstream applications or alternative delivery technologies is advisable for competitors.
Key Takeaways
- Claims define a focused, potentially strong IP position centered on specific formulation and method claims, which are critical in pharmaceutical patent landscapes.
- Global filing strategies suggest a proactive approach to securing patent rights across key markets, prolonging market exclusivity.
- The scope of IL264510 warrants careful review when developing bioavailability-enhancing formulations to avoid infringement or leverage licensing.
- Patent challenges should focus on prior art related to nanoparticle and lipid-based delivery systems, requiring detailed legal and technical analysis.
- Stakeholders must update their IP strategies continually, considering emerging biosimilars, generics, and formulation innovations.
FAQs
1. What makes IL264510's claims unique compared to prior art?
The patent's claims are unique if they involve specific combinations of excipients, nanoparticulate features, or process steps that were not previously disclosed. Its novelty hinges on these technical details, which purportedly lead to superior bioavailability.
2. How does this patent influence generic drug development?
It potentially blocks the development of generic formulations with identical delivery systems and compositions in Israel. Developers must find new formulations or methods that do not infringe.
3. Can IL264510 be challenged or invalidated?
Yes, via prior art searches, opposition proceedings, or validity challenges based on obviousness or lack of inventive step. The strength depends on the depth of prior art and prosecutorial history.
4. What is the importance of the patent's jurisdictional scope?
While Israel-specific, filing family members in major markets extends protection and influences global competitive dynamics, especially if patent claims are harmonized or have counterparts.
5. How does patent IL264510 impact R&D investment?
The patent justifies R&D investment by providing exclusivity, competitive advantage, and potential licensing revenue if effectively enforced or licensed.
References
- Israeli Patent Office. Patent IL264510 document and related family filings.
- USPTO patent search database for related patent family members.
- Patent landscape analysis reports from global patent databases (e.g., PatSeer, Derwent Innovation).
- Scientific literature on bioavailability enhancement techniques, nanoparticle delivery, and formulation patents.
Note: The detailed technical and legal specifics depend on actual claim language, patent prosecution history, and prior art references, which are beyond the scope of this summarization without access to the complete patent document. For legal advice or patent strategy specifics, consult a patent attorney with expertise in pharmaceutical patents.
